TC BioPharm (Holdings) PLC, a clinical-stage biotechnology company specializing in allogeneic gamma-delta T cell therapies for cancer and other ailments, has unveiled plans to revolutionize its manufacturing process, paving the way for a significant increase in treatment capacity and a remarkable 85 percent reduction in per-patient costs.

The company's initiative aims to leverage its existing infrastructure to scale up production dramatically, projecting a surge from 52 patient treatments annually to over 1,000. This monumental undertaking is poised to not only strengthen treatment accessibility but also drive down expenses, marking a pivotal moment in the advancement of cell therapy.

Dr. Lauren Bor, Ph.D., Senior Manager of Process Development and Commercialization at TC BioPharm, expressed confidence in the transformative impact of these endeavors stating, "These new initiatives will allow us to increase capacity while simultaneously reducing the cost of our per-patient treatment once optimized."

Highlighting the pressing need for such innovations in the field, Dr. Bor emphasized the challenges posed by the exorbitant costs associated with cell therapy manufacturing. By addressing this critical bottleneck, TC BioPharm is poised to redefine the landscape of therapeutic accessibility, ensuring that patients can benefit from cost-effective treatments without compromising on quality.

"This enterprise is necessary to address the challenging operating landscape in cell therapy and better position TC BioPharm both economically and operationally to improve the lives of patients while creating long-term value for shareholders," Dr. Bor added.

The company anticipates implementing the enhanced manufacturing process within the next 24 months, highlighting its commitment to driving tangible progress in the realm of biotechnology. Furthermore, these developments are expected to lay the groundwork for an expansive commercialization plan, further solidifying TC BioPharm's position as a leader in the field.